Table 1.
Frequencies of breast cancer subtype according to race.
| Study (reference) | Tumor type | NHW number (%) | AA number (%) |
|---|---|---|---|
| Vallega et al. (10) | Luminal A | 296 (42.05) | 27 (21.95) |
| Luminal B | 75 (10.65) | 3 (2.44) | |
| HER2 type | 19 (2.70) | 4 (3.25) | |
| Triple negative | 66 (9.38) | 24 (19.51) | |
| Other N/A | 248 (35.23) | 65 (52.85) | |
| Kwan et al. (11) | Luminal A | 1,464 (75.3) | 92 (59.4) |
| Luminal B | 215 (11.1) | 14 (9.0) | |
| HER2 type | 60 (3.1) | 5 (3.2) | |
| Triple negative | 204 (10.5) | 44 (28.4) | |
| Lund et al. (12) | ER/PR+HER2- | 231 (64.3) | 41 (38.7) |
| ER/PR+HER2+ | 29 (7.9) | 7 (6.1) | |
| ER/PR-HER2+ | 21 (6.0) | 12 (8.7) | |
| Triple negative | 79 (21.8) | 56 (46.6) | |
| Sineshaw et al. (13) | HR+HER2- | 126,856 (66.8) | 15,253 (51.7) |
| HR+HER2+ | 16,896 (8.9) | 2,948 (10.0) | |
| HR-HER2+ | 7,130 (3.8) | 1,463 (5.0) | |
| Triple negative | 19,375 (10.2) | 6,231 (21.1) | |
| Other N/A | 19,620 (10.3) | 3,590 (12.2) | |
| Stewart et al. (14) | Luminal A | 243 (42.33) | 16 (30.19) |
| Luminal B | 62 (10.80) | 0 (0.00) | |
| HER2 type | 17 (2.96) | 3 (5.66) | |
| Triple negative | 67 (11.67) | 10 (18.87) | |
| Other N/A | 185 (32.23) | 24 (45.28) | |
| Plasilova et al. (15) | HR+ HER2- | 175,760 (74.8) | 20,255 (59.6) |
| HR+ HER2+ | 22,870 (9.7) | 3,744 (11.0) | |
| HR- HER2+ | 9,669 (4.1) | 1,904 (5.6) | |
| Triple-negative | 26,783 (11.4) | 8,067 (23.7) |
HR, hormone receptor; ER/PR, estrogen receptor/progesterone receptor; HER2, human epidermal growth factor receptor 2; Luminal A, ER+ and/or PR+ HER2−; Luminal B, ER+ and/or PR+ HER2+; Triple negative, ER/PR− HER2−; N/A, not available.